Image
Article
05:09
MSL News 23: Independencia de Lp(a) y c-LDL en el riesgo cardiovascular - Dr. Ramón Costa
Article - 02 Jul 2025
05:09
Article
07:50
MSL News 22: Registro cholinet - Dra. Rosa Sánchez
Article - 19 Mayo 2025
07:50
Article
06:42
MSL News 21: Uso de nuevas terapias hipolipemiantes en la práctica clínica. Documento de consenso – Dr. Alberto Cordero
Article
09:06
MSL News 20: Inclisirán VICTORION INITIATE - Dra. Amelia Carro
Article - 19 Mayo 2025
09:06
Article
09:19
MSL News 19: Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials
Article - 19 Mayo 2025
09:19
Article
09:44
MSL News 18: Lipid lowering with inclisiran: a real-world single-centre experience – Dr. Antonio García Quintana
Article - 19 Mayo 2025
09:44
Article
08:35
MSL News 17: ORION-8: Eficacia y seguridad a largo plazo de la administración de dos veces al año
Article - 19 Mayo 2025
08:35
de inclisirán en pacientes de alto riesgo cardiovascular - Dra. Miriam Martín
Article
07:21
MSL News 16: Estimating the potential impact of LDL-C lowering through siRNA therapies on population health
Article - 19 Mayo 2025
07:21
A simulation study – Dr. Carlos Guijarro
Article
07:35
MSL News 15: A pooled safety analysis of inclisiran in 3576 patients with approximately 10,000 person-years of exposure
Article - 19 Mayo 2025
07:35
from seven trials – Dra. Marisol Bravo
Article
06:04
MSL News 14: Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk
Article - 19 Mayo 2025
06:04
and elevated low-density lipoprotein cholesterol (ORION-3): Results from the 4-year open-label extension of the ORION-1 trial – Dr. Armando Oterino
Article
09:40
MSL News 13: Combination lipid-lowering therapy as first-line strategy in very high-risk patients – Dr. Luís Masana
Article - 19 Mayo 2025
09:40
Article
07:00
MSL News 12: 2022 el año de la enfermedad cardiovascular – Dr. José María Gámez
Article - 19 Mayo 2025
07:00
Article
03:25
MSL News 11: Inclisiran and cardiovascular events: a patient-level analysis of phase III trials – Dra. Rosa Fernández
Article
04:59
MSL News 10: Farmacocinética, farmacodinámica y seguridad de inclisirán
Article - 19 Mayo 2025
04:59
Article
07:18
MSL News 9: Estándares SEA 2022
Article - 19 Mayo 2025
07:18
Article
03:15
MSL News 8: Ray K.: tratamiento hipolipemiante combinado
Article - 19 Mayo 2025
03:15
Article
04:22
MSL News 7: Opiniones científicas: prevención cardiovascular
Article - 19 Mayo 2025
04:22
Article
04:22
MSL News 6: Warden
Article - 19 Mayo 2025
04:22
Article
04:22
MSL News 5: Damase
Article - 19 Mayo 2025
04:22
Article
04:22
MSL News 4: Reducción intensiva del cLDL en la prevención CV
Article - 19 Mayo 2025
04:22
Article
04:22
MSL News 3: Cartas científicas: grado de control del cLDL en España
Article - 19 Mayo 2025
04:22
Article
03:30
MSL News 2: Swedeheart
Article - 19 Mayo 2025
03:30
Article
04:48
MSL News 1: Inclisirán
Article - 19 Mayo 2025
04:48
Image
